Immunoglobulins, specifically intravenous immunoglobulin (IVIG), have significant scientific validation for use in treating various autoimmune disorders. IVIG is a blood product consisting of pooled IgG antibodies extracted from the plasma of thousands of donors. Its use is supported by a considerable body of clinical evidence for several autoimmune conditions, including immune thrombocytopenia (ITP), Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), Kawasaki disease, and myasthenia gravis, among others.

The mechanism by which IVIG works in autoimmune diseases is complex and multifactorial. Proposed mechanisms include modulation of Fc receptor function, neutralization of autoantibodies, suppression of inflammatory cytokines, and interference with the complement system. These effects lead to a reduction in the harmful immune responses that drive autoimmune pathology.

Multiple double-blind, placebo-controlled trials and systematic reviews have demonstrated the efficacy of IVIG in improving clinical outcomes and reducing disease activity in several autoimmune disorders. For instance, IVIG is recommended as first- or second-line therapy in ITP and is a mainstay of treatment in acute Guillain-Barré syndrome. Safety profiles have also been well characterized, making it a widely accepted therapy in clinical practice.

In summary, the use of immunoglobulins in autoimmune disorders is strongly supported by high-quality scientific evidence, and their clinical benefits are recognized in international treatment guidelines for multiple autoimmune diseases.